文献速递胸部肿瘤放疗

III期(N2)非小细胞肺癌术后放疗作用与复发预测因素分析

Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer.
PubMed 文献 · Adv Radiat Oncol · 2016-12-21

本研究回顾性分析1999年至2012年71例手术切除的III期(N2)非小细胞肺癌患者,评估局部区域复发危险因素及术后放疗对局部区域控制和总生存的影响。结果显示接受术后放疗者5年总生存和局部区域控制率数值更高,但差异无统计学意义。

核心结论

  • 在接受手术切除的III期(N2)非小细胞肺癌患者中,接受术后放疗者总生存和局部区域控制率数值上更高,但差异未达统计学显著性。

研究设计与样本

  • 回顾性分析1999年2月至2012年1月在本机构接受根治性切除的III期(N2)非小细胞肺癌患者共71例。
  • 采用Kaplan-Meier法从手术日期起估计总生存、局部区域控制和转移无生存。

主要发现

  • 患者中位年龄63岁,腺癌占69%,90%接受治疗前PET/CT分期,23%接受术前化疗,R0切除率96%。
  • 41例(58%)接受术后放疗,中位剂量50 Gy(范围41.4-60 Gy)。
  • 存活患者中位随访时间5.0年,所有患者5年总生存率为66%。

关键数值与推荐

  • 术后放疗中位剂量50 Gy,范围41.4-60 Gy。

临床怎么用

  • 对于手术切除的III期(N2)非小细胞肺癌,术后放疗可考虑用于改善局部区域控制,但需个体化权衡,因本研究未显示统计学显著获益。
  • 男性和pT3/4期患者局部区域复发风险较高,应加强术后随访和复发监测。

局限性

  • 本研究为单中心回顾性分析,样本量较小(71例),可能存在选择偏倚。
  • 术后放疗组与未放疗组之间的比较非随机化,混杂因素可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For patients with stage III (N2) non-small cell lung cancer (NSCLC) treated with surgical resection, postoperative chemotherapy improves overall survival (OS), but the role of postoperative radiation therapy (PORT) is controversial. The purpose of this study was to evaluate risk factors for local-regional recurrence and to evaluate the impact of PORT on local-regional control (LRC) and OS in a modern series of patients with surgically resected stage III (N2) NSCLC. METHODS AND MATERIALS: A retrospective review was performed of patients with Stage III (N2) NSCLC who underwent curative intent resection at our institution between February 1999 and January 2012. OS, LRC, and metastasis-free survival were estimated from the date of surgery using the Kaplan Meier method. RESULTS: A total of 71 patients were included in the study. Patient median age was 63 years. Histology was adenocarcinoma in 69% of patients. Pretreatment positron emission tomography/computed tomography staging was performed for 90% of patients, and preoperative chemotherapy was administered in 23%. The rate of R0 resection was 96%. Forty-one patients (58%) received PORT and the median PORT dose was 50 Gy (range, 41.4-60 Gy). The median follow-up time for living patients was 5.0 years. Five-year OS for all patients was 66%. OS at 5 years for patients who received PORT compared with patients who did not receive PORT was 71% versus 60%, respectively (hazard ratio [HR], 0.61; 95% CI, 0.30-1.44; P = .28). LRC at 5 years for patients who received PORT compared with patients who did not receive PORT was 89% versus 76%, respectively (HR, 0.44; 95% CI, 0.13-1.45; P = .17). Factors associated with decreased LRC were male sex (P = .011) and primary tumor (pT) stage (pT3/4 vs. pT1/2, P = .006). Metastasis-free survival at 5 years for patients who received PORT compared with those who did not receive PORT was 62% versus 63%, respectively (HR, 1.07; 95% CI, 0.51-2.40; P = .86). CONCLUSIONS: In this modern series of patients with resected stage III (N2) NSCLC, patients who received PORT had higher rates of OS and LRC, but these differences were not statistically significant.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Breen WG, Merrell KW, Mansfield AS, et al. Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer. Adv Radiat Oncol. 2016. PMID: 28740911. doi:10.1016/j.adro.2016.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。